Dr. Olivier Micheau is a research director of the INSERM (French National Institute of Health), UMR1231. He received his PhD in  Biochemistry and Molecular and Cellular Biology in 1999 from the University of Burgundy, France. He next moved as a post-doctoral fellow in Jurg Tschopp’s laboratory in Epalinges, Switzerland, from 1999 to 2003, where he elucidated the molecular mechanisms underlying TNFR1’s dual signaling ability. He described for the first time TNFR1 cytosolic pro-apoptotic complex II. In 2003 he joined the INSERM unit U517 headed by Professor E. Solary in Dijon, France, as an INSERM researcher. Member of several scientific councils, including INSERM CSS3 (2012-2016) and Fondation ARC pour la recherche sur le cancer, a French Charity (since 2015), he is also Associate Editor of the British Journal of Pharmacology since 2012. His scientific interest focuses on TRAIL receptor signaling and its use in cancer therapy.

• Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer.- TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer.- IAPs and Resistance to Death Receptors in Cancer.- Bcl-2 Proteins and TRAIL Resistance in Melanoma.- Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4.- Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy.- Atypical Immune Functions of CD95/CD95L.- TLR3 is a Death Receptor Target in Cancer Therapy.- Fas/CD95, Lipid Rafts and Cancer.- Role of Sphingolipids in Death Receptor Signalling.- Post-Translational Modifications and Death Receptor Signalling.- System Modeling of Receptor-Induced Apoptosis.